L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma
NCT06478381
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
22
Enrollment
OTHER_GOV
Sponsor class
Conditions
Relapsed/Refractory B-cell Lymphomas
Interventions
DRUG:
L218CAR19
Sponsor
Henan Cancer Hospital